The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies
Open accessAbstract
Nonsyndromic recessive retinal dystrophies cause severe visual impairment due to the death of photoreceptor and retinal pigment epithelium cells.These diseases until recently have been considered to be incurable.Molecular genetic studies in the last two decades have revealed the underlying molecular causes in approximately two-thirds of patients.The mammalian eye has been at the forefront of therapeutic trials based on gene augmentation in humans with an early-onset nonsyndromic recessive retinal dystrophy due to mutations in the retinal pigment epithelium-specific protein 65kDa (RPE65) gene.Tremendous challenges still lie ahead to extrapolate these studies to other retinal disease-causing genes, as human gene augmentation studies require testing in animal models for each individual gene and sufficiently large patient cohorts for clinical trials remain to be identified through cost-effective mutation screening protocols. Phenotypes of inherited nonsyndromic retinal diseasesGeneralized and/or peripheral retinal dystrophies.Retinitis pigmentosa (RP) represents the most frequent cause of inherited visual impairment, with a worldwide prevalence of 1:4,000 (1).It encompasses a clinically heterogeneous group of progressive disorders that primarily affect the function of the photoreceptors and the RPE (2).There is a large variability in the age of onset, progression, retinal appearance, and final visual outcome.Pigment granules from the RPE migrate to perivascular sites of the neural retina secondary to photoreceptor death, forming the hallmark "bone spicules" (Figure 1C).The attenuation of the retinal arterioles and veins probably also represents a secondary effect of photoreceptor cell death.Initially, rods are predominantly affected, resulting in night blindness and tunnel vision.Later in the disease process, cones also are affected, which can result in complete blindness (1).Thirty percent of RP patients show AR inheritance, 20% show AD inheritance, and 10% show XL inheritance (2).Approximately 40% of RP patients represent isolated cases.Conflict of interest: Jean Bennett is a co-inventor on the pending patent "A Method of Treating or Retarding the Development of Blindness" but waived any financial interest in this technology in 2002.Jean Bennett presented a seminar at Novartis in 2009.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationExome sequencing identifies the cause of a mendelian disorder
Ng, S. B., Buckingham, K. J., Lee, C., Bigham, A. W., Tabor, H. K., Dent, K. M., Huff, C. D., Shannon, P. T., Jabs, E. W., Nickerson, D. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.499 · Cited by 1,957
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Allikmets, R., Singh, N., Sun, H., Shroyer, N. F., Hutchinson, A., Chidambaram, A., Gerrard, B., Baird, L., Stauffer, D., Peiffer, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0397-236 · Cited by 1,435
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Nrl is required for rod photoreceptor development
Mears, A. J., Kondo, M., Swain, P. K., Takada, Y., Bush, R. A., Saunders, T. L., Sieving, P. A., & Swaroop, A. (2001) · Nature Genetics · doi:10.1038/ng774 · Cited by 912
Weng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., & Travis, G. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80602-9 · Cited by 881
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Self-citation
Cited by
Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases
Hanany, M., Rivolta, C., & Sharon, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913179117 · Cited by 408
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Self-citationNext‐generation genetic testing for retinitis pigmentosa
Neveling, K., Collin, R. W. J., Gilissen, C., van Huet, R. A. C., Visser, L., Kwint, M. P., Gijsen, S. J., Zonneveld, M. N., Wieskamp, N., de Ligt, J., et al. (2012) · Human Mutation · doi:10.1002/humu.22045 · Cited by 286
Self-citationAbu-Safieh, L., Alrashed, M., Anazi, S., Alkuraya, H., Khan, A. O., Al-Owain, M., Al-Zahrani, J., Al-Abdi, L., Hashem, M., Al-Tarimi, S., et al. (2013) · Genome Research · doi:10.1101/gr.144105.112 · Cited by 276
Key enzymes of the retinoid (visual) cycle in vertebrate retina
Kiser, P. D., Golczak, M., Maeda, A., & Palczewski, K. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.03.005 · Cited by 177
“major success story in the gene therapy field [160–164].”
Immunology of AAV-Mediated Gene Transfer in the Eye
Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105
“In the eye these responses have been much less than those induced by systemically injected AAV by several log units (30).”
BackgroundSelf-citationBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
AAV9 targets cone photoreceptors in the nonhuman primate retina
Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053463 · Cited by 97
Self-citationAdvances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
“A case in point is the gene replacement therapy for the retina-specific guanylate cyclase (GUCY2D), which is expressed exclusively in rods and cones and constitutes one of the most common causes of LCA.(61) The GC1-deficient mouse undergoes severe cone dysfunction before cone degeneration.”
BackgroundInfluentialCukras, C., Gaasterland, T., Lee, P., Gudiseva, H. V., Chavali, V. R. M., Pullakhandam, R., Maranhao, B., Edsall, L., Soares, S., Reddy, G. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050205 · Cited by 65
An ABCA4 loss-of-function mutation causes a canine form of Stargardt disease
Mäkeläinen, S., Gòdia, M., Hellsand, M., Viluma, A., Hahn, D., Makdoumi, K., Zeiss, C. J., Mellersh, C., Ricketts, S. L., Narfström, K., et al. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1007873 · Cited by 41
Dietary 9-cis-β,β-Carotene Fails to Rescue Vision in Mouse Models of Leber Congenital Amaurosis
Maeda, T., Perusek, L., Amengual, J., Babino, D., Palczewski, K., & von Lintig, J. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074732 · Cited by 37
Optimized Subretinal Injection Technique for Gene Therapy Approaches
Mühlfriedel, R., Michalakis, S., Garrido, M. G., Sothilingam, V., Schön, C., Biel, M., & Seeliger, M. W. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8669-9_26 · Cited by 14
Metadata
- Authors
- den Hollander, A. I., Black, A., Bennett, J., & Cremers, F. P. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-09-01
- Volume
- 120
- Issue
- 9
- Pages
- 3042-3053
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2042293587
- Cited by
- 207
- References
- 32
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.